Time Technoplast Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 25, 2025, 8:02 pm

Competitors of Time Technoplast Ltd

All Competitor Stocks of Time Technoplast Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:30 am

Below is a detailed analysis of the quarterly data for Time Technoplast Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 1,469.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,388.00 Cr. (Dec 2024) to 1,469.00 Cr., marking an increase of 81.00 Cr..
• For Expenses, as of Mar 2025, the value is 1,255.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,187.00 Cr. (Dec 2024) to 1,255.00 Cr., marking an increase of 68.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 214.00 Cr.. The value appears strong and on an upward trend. It has increased from 201.00 Cr. (Dec 2024) to 214.00 Cr., marking an increase of 13.00 Cr..
• For OPM %, as of Mar 2025, the value is 15.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Dec 2024) to 15.00%, marking an increase of 1.00%.
• For Other Income, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 2.00 Cr..
• For Interest, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 22.00 Cr..
• For Depreciation, as of Mar 2025, the value is 44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Dec 2024) to 44.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 150.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Dec 2024) to 150.00 Cr., marking an increase of 13.00 Cr..
• For Tax %, as of Mar 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 25.00%.
• For Net Profit, as of Mar 2025, the value is 112.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Dec 2024) to 112.00 Cr., marking an increase of 10.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 4.83. The value appears strong and on an upward trend. It has increased from 4.44 (Dec 2024) to 4.83, marking an increase of 0.39.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:42 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:11 am

Below is a detailed analysis of the balance sheet data for Time Technoplast Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 23.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,869.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,530.00 Cr. (Mar 2024) to 2,869.00 Cr., marking an increase of 339.00 Cr..
• For Borrowings, as of Mar 2025, the value is 732.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 829.00 Cr. (Mar 2024) to 732.00 Cr., marking a decrease of 97.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 775.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 732.00 Cr. (Mar 2024) to 775.00 Cr., marking an increase of 43.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 4,399.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,114.00 Cr. (Mar 2024) to 4,399.00 Cr., marking an increase of 285.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,373.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,368.00 Cr. (Mar 2024) to 1,373.00 Cr., marking an increase of 5.00 Cr..
• For CWIP, as of Mar 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2024) to 79.00 Cr., marking an increase of 38.00 Cr..
• For Investments, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
• For Other Assets, as of Mar 2025, the value is 2,943.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,703.00 Cr. (Mar 2024) to 2,943.00 Cr., marking an increase of 240.00 Cr..
• For Total Assets, as of Mar 2025, the value is 4,399.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,114.00 Cr. (Mar 2024) to 4,399.00 Cr., marking an increase of 285.00 Cr..

Notably, the Reserves (2,869.00 Cr.) exceed the Borrowings (732.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Time Technoplast Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 17.10. This value is within the healthy range. It has increased from 13.71 (Mar 24) to 17.10, marking an increase of 3.39.
• For Diluted EPS (Rs.), as of Mar 25, the value is 17.10. This value is within the healthy range. It has increased from 13.67 (Mar 24) to 17.10, marking an increase of 3.43.
• For Cash EPS (Rs.), as of Mar 25, the value is 24.86. This value is within the healthy range. It has increased from 21.53 (Mar 24) to 24.86, marking an increase of 3.33.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.46. It has increased from 112.39 (Mar 24) to 127.46, marking an increase of 15.07.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 127.46. It has increased from 112.49 (Mar 24) to 127.46, marking an increase of 14.97.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 240.50. It has increased from 220.00 (Mar 24) to 240.50, marking an increase of 20.50.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 34.83. This value is within the healthy range. It has increased from 31.07 (Mar 24) to 34.83, marking an increase of 3.76.
• For PBIT / Share (Rs.), as of Mar 25, the value is 27.35. This value is within the healthy range. It has increased from 23.46 (Mar 24) to 27.35, marking an increase of 3.89.
• For PBT / Share (Rs.), as of Mar 25, the value is 23.32. This value is within the healthy range. It has increased from 18.99 (Mar 24) to 23.32, marking an increase of 4.33.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 17.38. This value is within the healthy range. It has increased from 13.92 (Mar 24) to 17.38, marking an increase of 3.46.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.10. This value is within the healthy range. It has increased from 13.68 (Mar 24) to 17.10, marking an increase of 3.42.
• For PBDIT Margin (%), as of Mar 25, the value is 14.48. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 14.48, marking an increase of 0.36.
• For PBIT Margin (%), as of Mar 25, the value is 11.37. This value is within the healthy range. It has increased from 10.66 (Mar 24) to 11.37, marking an increase of 0.71.
• For PBT Margin (%), as of Mar 25, the value is 9.69. This value is below the healthy minimum of 10. It has increased from 8.63 (Mar 24) to 9.69, marking an increase of 1.06.
• For Net Profit Margin (%), as of Mar 25, the value is 7.22. This value is within the healthy range. It has increased from 6.32 (Mar 24) to 7.22, marking an increase of 0.90.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.10. This value is below the healthy minimum of 8. It has increased from 6.21 (Mar 24) to 7.10, marking an increase of 0.89.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.41. This value is below the healthy minimum of 15. It has increased from 12.17 (Mar 24) to 13.41, marking an increase of 1.24.
• For Return on Capital Employeed (%), as of Mar 25, the value is 18.70. This value is within the healthy range. It has increased from 17.93 (Mar 24) to 18.70, marking an increase of 0.77.
• For Return On Assets (%), as of Mar 25, the value is 8.81. This value is within the healthy range. It has increased from 7.54 (Mar 24) to 8.81, marking an increase of 1.27.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.22. This value is within the healthy range. It has decreased from 0.29 (Mar 24) to 0.22, marking a decrease of 0.07.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.28. It has increased from 1.26 (Mar 24) to 1.28, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.33 (Mar 24) to 2.68, marking an increase of 0.35.
• For Quick Ratio (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has increased from 1.41 (Mar 24) to 1.62, marking an increase of 0.21.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.54. This value is below the healthy minimum of 4. It has increased from 3.50 (Mar 24) to 3.54, marking an increase of 0.04.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 9.48 (Mar 24) to 0.00, marking a decrease of 9.48.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.09 (Mar 24) to 0.00, marking a decrease of 6.09.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 90.52 (Mar 24) to 0.00, marking a decrease of 90.52.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.91 (Mar 24) to 0.00, marking a decrease of 93.91.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 8.63. This value is within the healthy range. It has increased from 6.95 (Mar 24) to 8.63, marking an increase of 1.68.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.31. This value is within the healthy range. It has increased from 4.11 (Mar 24) to 5.31, marking an increase of 1.20.
• For Enterprise Value (Cr.), as of Mar 25, the value is 10,015.13. It has increased from 6,314.29 (Mar 24) to 10,015.13, marking an increase of 3,700.84.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.84. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.84, marking an increase of 0.58.
• For EV / EBITDA (X), as of Mar 25, the value is 12.67. This value is within the healthy range. It has increased from 8.96 (Mar 24) to 12.67, marking an increase of 3.71.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 1.74, marking an increase of 0.61.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 90.51 (Mar 24) to 0.00, marking a decrease of 90.51.
• For Price / BV (X), as of Mar 25, the value is 3.28. This value exceeds the healthy maximum of 3. It has increased from 2.22 (Mar 24) to 3.28, marking an increase of 1.06.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 1.74, marking an increase of 0.61.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness